Understanding the Market | RemeGen rose nearly 5% as 10 research projects were showcased at ESMO, institutions optimistic about its accelerated overseas expansion
I'm PortAI, I can summarize articles.
RemeGen's stock price rose nearly 5%, up 4.81% as of the time of publication, trading at HKD 96.95, with a transaction volume of HKD 706 million. The company presented 10 studies at the 2025 European Society for Medical Oncology (ESMO) annual meeting, with the Phase III study data of Vadastuximab being published for the first time and set to be featured in the New England Journal of Medicine. Huatai Securities believes that the global competitiveness of the company's pipeline will accelerate overseas expansion, maintaining a "Buy" rating
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments